Precision BioSciences (DTIL) Expected to Announce Quarterly Earnings on Monday

Precision BioSciences (NASDAQ:DTIL) is expected to be posting its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Precision BioSciences to post earnings of ($0.31) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, November 3, 2025 at 7:00 AM ET.

Precision BioSciences (NASDAQ:DTIL) last announced its earnings results on Thursday, August 7th. The company reported ($2.13) EPS for the quarter, missing the consensus estimate of ($0.09) by ($2.04). Precision BioSciences had a negative net margin of 6,205.79% and a negative return on equity of 176.47%. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $6.27 million. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Trading Down 5.2%

NASDAQ:DTIL opened at $8.16 on Friday. The stock has a fifty day simple moving average of $5.71 and a 200 day simple moving average of $5.16. The firm has a market capitalization of $96.21 million, a price-to-earnings ratio of -0.93 and a beta of 1.72. Precision BioSciences has a 1-year low of $3.61 and a 1-year high of $9.14. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.66.

Institutional Investors Weigh In On Precision BioSciences

Institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC purchased a new position in shares of Precision BioSciences during the 2nd quarter valued at $425,000. Geode Capital Management LLC boosted its position in Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after purchasing an additional 4,025 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in Precision BioSciences during the second quarter valued at $260,000. Institutional investors and hedge funds own 37.99% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Precision BioSciences in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $47.00.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.